| Literature DB >> 32514489 |
Tahereh Gheliji1, Vahid Kholghi Oskooei2,3, Asghar Ashrafi Hafez4, Mohammad Taheri5, Soudeh Ghafouri-Fard6.
Abstract
Lung cancer as the most common cancer in the world is associated with high rate of mortality. Previous studies have detected expression of vitamin D receptor (VDR) in lung cancer tissues and reported significant of this gene in determination of patients' survival.Entities:
Keywords: Lung cancer; Vitamin D receptor; lncRNA
Year: 2020 PMID: 32514489 PMCID: PMC7264462 DOI: 10.1016/j.ncrna.2020.05.001
Source DB: PubMed Journal: Noncoding RNA Res ISSN: 2468-0540
General data of patients (AC: adenocarcinoma, SCC: squamous cell carcinoma).
| Parameters | Values | |
|---|---|---|
| Age (Mean ± standard deviation (range)) | 57 ± 8.78 (37-80) | |
| Gender (%) | Male | 71.4% |
| Female | 28.6% | |
| Subtype (%) | AC | 57.1% |
| SCC | 42.9% | |
| Stage (%) | I | 19% |
| II | 38.1% | |
| III | 42.9% | |
| Smoking (%) | Yes | 19% |
| No | 81% | |
Fig. 1Expression of VDR and its related lncRNAs in lung cancer tissues and ANCTs.
Relative expression of VDR and lncRNAs in lung cancer tissues compared with ANCTs.
| Genes | Parameters | Total patients (n = 42) | Male patient (n = 31) | Female patients (n = 11) |
|---|---|---|---|---|
| Expression ratio | 0.61 | 0.4 | 1.98 | |
| P-value | 0.25 | 0.08 | 0.38 | |
| Expression ratio | 0.49 | 0.42 | 0.78 | |
| P-value | 0.11 | 0.09 | 0.79 | |
| Expression ratio | 0.38 | 0.3 | 0.74 | |
| P-value | 0.03 | 0.04 | 0.65 | |
| Expression ratio | 0.65 | 0.56 | 0.99 | |
| P-value | 0.34 | 0.28 | 0.99 | |
| Expression ratio | 0.83 | 0.8 | 0.92 | |
| P-value | 0.7 | 0.73 | 0.88 | |
| Expression ratio | 0.42 | 0.31 | 0.93 | |
| P-value | 0.05 | 0.02 | 0.94 |
Association between expression of genes and clinical data (AC: adenocarcinoma, SCC: squamous cell carcinoma).
| P value | P value | P value | P value | P value | P value | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age | 0.58 | 0.78 | 0.8 | 0.53 | 0.36 | 0.38 | ||||||||||||
| >60 | 7 (31.8%) | 15 (68.2%) | 9 (40.9%) | 13 (59.1%) | 8 (36.4%) | 14 (63.6%) | 12 (54.5%) | 10 (45.5%) | 13 (59.1%) | 9 (40.9%) | 6 (27.3%) | 16 (72.7%) | ||||||
| ≤60 | 8 (40%) | 12 (60%) | 9 (45%) | 11 (55%) | 8 (40%) | 12 (60%) | 9 (45%) | 11 (55%) | 9 (45%) | 11 (55%) | 8 (40%) | 12 (60%) | ||||||
| Sex | 1 | 0.08 | 0.68 | 0.49 | 0.37 | 0.03 | ||||||||||||
| Female | 11 (36.7%) | 19 (63.3%) | 10 (33.3%) | 20 (66.7%) | 12 (40%) | 18 (60%) | 16 (53.3%) | 14 (46.7%) | 17 (56.7%) | 13 (43.3%) | 5 (23.3%) | 23 (76.7%) | ||||||
| Male | 4 (33.3%) | 8 (66.7%) | 8 (66.7%) | 4 (33.3%) | 4 (33.3%) | 8 (66.7%) | 5 (41.7%) | 7 (58.3%) | 5 (41.7%) | 7 (58.3%) | 7 (58.3%) | 5 (41.7%) | ||||||
| Subtype | 0.3 | 0.85 | 0.58 | 1 | 0.37 | 0.5 | ||||||||||||
| AC | 7 (29.2%) | 17 (70.8%) | 10 (41.7%) | 14 (58.3%) | 10 (41.7%) | 14 (58.3%) | 12 (50%) | 12 (50%) | 14 (58.3%) | 10 (41.7%) | 9 (37.5%) | 15 (62.5%) | ||||||
| SCC | 8 (44.4%) | 10 (55.6%) | 8 (44.4%) | 10 (55.6%) | 6 (33.3%) | 12 (66.7%) | 9 (50%) | 9 (50%) | 8 (44.4%) | 10 (55.6%) | 5 (27.8%) | 13 (72.2%) | ||||||
| Stage | 0.53 | 0.43 | 0.47 | 0.67 | 0.56 | 0.11 | ||||||||||||
| I | 4 (50%) | 4 (50%) | 5 (62.5%) | 3 (37.5%) | 4 (50%) | 4 (50%) | 5 (62.5%) | 3 (37.5%) | 4 (50%) | 4 (50%) | 3 (37.5%) | 5 (62.5%) | ||||||
| II | 6 (37.5%) | 10 (62.5%) | 7 (43.8%) | 9 (56.2%) | 7 (43.8%) | 9 (56.3%) | 7 (43.8%) | 9 (56.3%) | 10 (62.5%) | 6 (37.5%) | 8 (50%) | 8 (50%) | ||||||
| III | 5 (27.8%) | 13 (72.2%) | 6 (33.3%) | 12 (66.7%) | 5 (27.8%) | 13 (72.2%) | 9 (50%) | 9 (50%) | 8 (44.4%) | 10 (55.6%) | 3 (16.7%) | 15 (83.3%) | ||||||
| Smoking | 1 | 0.25 | 1 | 1 | 0.44 | 1 | ||||||||||||
| Yes | 3 (37.5%) | 5 (62.5%) | 5 (62.5%) | 3 (37.5%) | 3 (37.5%) | 5 (62.5%) | 4 (50%) | 4 (50%) | 3 (37.5%) | 5 (62.5%) | 3 (37.5%) | 5 (62.5%) | ||||||
| No | 12 (35.3%) | 22 (64.7%) | 13 (38.2%) | 21 (61.8%) | 13 (38.2%) | 21 (61.8%) | 17 (50%) | 17 (50%) | 19 (55.9%) | 15 (44.1%) | 11 (32.4%) | 23 (67.6%) | ||||||
Correlation coefficients between expression levels of VDR and associated lncRNAs (*denotes P values less than 0.05, ** denotes P values less than 0.01).
| Genes | ||||||
|---|---|---|---|---|---|---|
| Tumor Tissues | 0.16* | 0.39** | 0.41** | 0.43** | 0.69** | |
| ANCTs | 0.001 | 0.04 | 0.05 | 0.05 | 0.06 | |
| Tumor Tissues | 0.26** | 0.39** | 0.53** | 0.56** | ||
| ANCTs | 0.1* | 0.22* | 0.31** | 0.34** | ||
| Tumor Tissues | 0.25* | 0.5** | 0.74 | |||
| ANCTs | 0.1* | 0.67** | 0.83** | |||
| Tumor Tissues | 0.24* | 0.36** | ||||
| ANCTs | 0.14* | 0.67** | ||||
| Tumor Tissues | 0.2* | |||||
| ANCT | 0.02 | |||||
Fig. 2ROC curve for assessment of diagnosis power of LINC00346 in lung cancer.